

## Liletta<sup>®</sup> (levonorgestrel-releasing intrauterine system) – Expanded indication

- On November 14, 2022, <u>Medicines360 announced</u> the <u>FDA approval</u> of <u>Liletta (levonorgestrel-releasing intrauterine system)</u>, for prevention of pregnancy for up to 8 years.
  - Liletta was previously approved for this indication for up to 6 years.
- The approval of Liletta for the expanded indication was based on a review of additional efficacy and safety data from ACCESS IUS, a randomized, open-label study in 1,751 U.S. women receiving Liletta. The pregnancy rate calculated as the Pearl Index (PI) in participants 16 to 35 years of age, inclusive, was the primary efficacy endpoint used to assess contraceptive reliability. The PI was calculated based on 28-day equivalent exposure cycles; evaluable cycles excluded those in which back-up contraception was used unless a pregnancy occurred in that cycle.
  - The year-by-year PI in year 7 was 0.49 (95% CI: 0.06, 1.78) and in year 8 it was 0.00 (95% CI: 0.00, 1.31).
- Liletta contains 52 mg of levonorgestrel (LNG). Initially, LNG is released *in vivo* at a rate of approximately 20 mcg/day. This rate decreases progressively to approximately 6.5 mcg/day after 8 years.
  - Liletta can be removed at any time but must be removed by the end of the eighth year.
    Liletta can be replaced at the time of removal with a new Liletta if continued contraceptive protection is desired.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews<sup>®</sup> is published by the Optum Rx Clinical Services Department.